An Extension Study to Evaluate the Long-Term Safety and Tolerability of UTTR1147A in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease

  • Autoimmune Disorder
  • Crohn's Disease
  • Inflammatory Bowel Disease (IBD)
  • Ulcerative Colitis
Please note that the recruitment status of the trial at your site may differ from the overall study status because some study sites may recruit earlier than others.
Trial Status:


This trial runs in
  • ballinasloe
  • Beograd
  • Berlin
  • Bydgoszcz
  • cascina-perseghetto
  • Chernivtsi
  • Chișinău
  • Częstochowa
  • Dresden
  • Düsseldorf
  • Elizabeth City
  • Gdańsk
  • Greenville
  • Irkutsk
  • Katowice
  • Kiel
  • Kielce
  • Kragujevac
  • Kropyvnytskyi
  • Kyiv
  • London
  • Lublin
  • Ludwigshafen am Rhein
  • Monza
  • Padova
  • Palaio Faliro
  • Piotrków Trybunalski
  • Plovdiv
  • Poznań
  • Roma
  • Samara
  • Sankt-Peterburg
  • Sliven
  • Sopot
  • T'bilisi
  • Ternopil
  • Thessaloniki
  • Torrejón de Ardoz
  • Uzhhorod
  • Vinnytsia
  • Vršac
  • Warszawa
  • Wrocław
  • Zaporizhzhia
  • Zhytomyr
  • Zrenjanin
  • Łódź
Trial Identifier:

NCT03650413 2017-004997-32 GA40209

      Show trial locations

      The source of the below information is public registry websites such as,,, etc.. It has been summarised and edited into simpler language. For more information about this clinical trial see the For Expert tab on the specific ForPatients page or follow these links to and/or and/or

      The below information is taken directly from public registry websites such as,,, etc., and has not been edited.

      Results Disclaimer

      Trial Summary

      This clinical trial was done to study a new medicine called, “efmarodocokin alfa”, for the treatment of patients with ulcerative colitis. This was a Phase 2 open-label extension study to find out the long-term safety and tolerability of efmarodocokin alfa in patients with moderate to severe ulcerative colitis. It was carried out at 66 study centers in fourteen countries.

      Genentech, Inc. (A part of F. Hoffmann-La Roche Ltd., Switzerland) Sponsor
      Phase 2 Phase
      NCT03650413,GA40209,2017-004997-32 Trial Identifier
      efmarodocokin alfa Treatments
      Ulcerative Colitis, Crohn's Disease Condition
      Official Title

      A Phase II Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of UTTR1147A in Patients With Moderate to Severe Ulcerative Colitis or Crohn's Disease

      Eligibility Criteria

      All Gender
      ≥ 18 Years & ≤ 80 Years Age
      No Healthy Volunteers
      Inclusion Criteria

      Inclusion Criteria for Study Entry:

      • Prior enrollment in Study GA29469 or Study GA39925 and meeting protocol defined entry criteria

      Inclusion Criteria for Study Entry and Study Re-Entry:

      • Ability to comply with requirements of the study, in the investigator's judgment
      • For women and men: use of highly effective contraception as defined by the protocol.
      Exclusion Criteria

      Exclusion Criteria for Study Entry:

      • Withdrawal of consent from parent study
      • Discontinuation of study drug as required by the parent study protocol
      • Discontinuation of study drug and withdrawal from Study GA29469 prior to Day 85 or from Study GA39925 prior to Week 8
      • Noncompliance in the parent study, specifically defined as missing scheduled visits or non-adherence with background medications and concomitant medications

      Exclusion Criteria for Study Entry and Study Re-Entry:

      • Pregnant or breastfeeding, or intending to become pregnant during the study or within 8 weeks after the final dose of study drug or within 18 weeks after the final dose of study drug from GA39925, whichever is longer
      • Any new malignancy, significant uncontrolled comorbidity, such as cardiac, pulmonary, renal, hepatic, endocrine, or gastrointestinal disorders, or signs or symptoms of infection judged by the investigator to be clinically significant since enrolling in the parent study
      • Use of prohibited therapies as defined in the parent study
      • Abnormal laboratory values, as defined in the protocol, recorded at the last visit in the parent study

      Exclusion Criterion for Study Re-Entry:

      • Use of prohibited concomitant therapy since enrolling in the extension study

      About Clinical Research

      What is a clinical trial? Why should I consider taking part in a clinical trial? And why does Genentech conduct clinical trials?

      Find out now